This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
February 14, 2012 9:00 am ET
Karen King -
Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance
Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of Research & Development & Medical Affairs
Gregory B. Gilbert - BofA Merrill Lynch, Research Division
Ami Fadia - UBS Investment Bank, Research Division
Louise A. Chen - Collins Stewart LLC, Research Division
Marshall Urist - Morgan Stanley, Research Division
David H. Roman - Goldman Sachs Group Inc., Research Division
Christopher Schott - JP Morgan Chase & Co, Research Division
Matthew Taylor - Barclays Capital, Research Division
Welcome to Hospira's Fourth Quarter and Full Year 2011 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference.
Thank you. Good morning, everyone, and welcome to our conference call and webcast regarding Hospira's financial results for the fourth quarter and full year 2011, as well as our projections for 2012. Participating in today's call are Mike Ball, Chief Executive Officer of Hospira; Tom Werner, Senior Vice President of Finance and Chief Financial Officer; and Sumant Ramachandra, Senior Vice President and Chief Scientific Officer.
We will be making some forward-looking statements today which are subject to risks and uncertainties and other factors that may cause actual results to differ materially from those indicated. A discussion of these factors is included in the risk factors and MD&A sections in Hospira's latest annual report on Form 10-K and subsequent Form 10-Qs on file with the SEC. We undertake no obligation to release publicly any revisions the forward-looking statements as a result of subsequent events or developments.